148 related articles for article (PubMed ID: 38343535)
1. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein.
Kroenke MA; Starcevic Manning M; Zuch de Zafra CL; Zhang X; Cook KD; Archer M; Lolkema MP; Wang J; Hoofring S; Saini G; Aeffner F; Ahern E; Cabanas EG; Govindan R; Hui M; Gupta S; Mytych DT
Front Immunol; 2024; 15():1345473. PubMed ID: 38343535
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of AMG 139, a human antibody specifically targeting IL-23.
Köck K; Pan WJ; Gow JM; Horner MJ; Gibbs JP; Colbert A; Goletz TJ; Newhall KJ; Rees WA; Sun Y; Zhang Y; O'Neill JC; Umble-Romero AN; Prokop SP; Krill CD; Som L; Buntich SA; Trimble MW; Tsuji WH; Towne JE
Br J Pharmacol; 2015 Jan; 172(1):159-72. PubMed ID: 25205227
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys.
Ji C; Kuang B; Buetow BS; Vitsky A; Xu Y; Huang TH; Chaparro-Riggers J; Kraynov E; Matsumoto D
PLoS One; 2024; 19(2):e0298240. PubMed ID: 38315680
[TBL] [Abstract][Full Text] [Related]
4. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
6. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.
Pan WJ; Hsu H; Rees WA; Lear SP; Lee F; Foltz IN; Rathanaswami P; Manchulenko K; Chan BM; Zhang M; Xia XZ; Patel SK; Prince PJ; Doherty DR; Sheckler CM; Reynhardt KO; Krill CD; Harder BJ; Wisler JA; Brandvig JL; Lynch JL; Anderson AA; Wienkers LC; Borie DC
Br J Pharmacol; 2013 May; 169(1):51-68. PubMed ID: 23425116
[TBL] [Abstract][Full Text] [Related]
8. Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target.
Kroenke MA; Barger TE; Hu J; Miller MJ; Kalenian K; He L; Hsu H; Bartley Y; Chow VF; Teixeira Dos Santos MC; Sullivan BA; Cheng LE; Parnes JR; Padaki R; Kuhns S; Mytych DT
Front Immunol; 2021; 12():782788. PubMed ID: 34970265
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
[TBL] [Abstract][Full Text] [Related]
12. Strategy and validation of a nonclinical generic plug-and-play antidrug antibody method for human monoclonal antibody biotherapeutics.
Polsky R; Gunn G; Reese KJ; Hottenstein CS; Gehman A; Schwartz A; Root D; Concannon A
Bioanalysis; 2024 Mar; 16(5):277-287. PubMed ID: 38334073
[TBL] [Abstract][Full Text] [Related]
13. Epitope characterization of the ADA response directed against a targeted immunocytokine.
Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
[TBL] [Abstract][Full Text] [Related]
14. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
15. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
[TBL] [Abstract][Full Text] [Related]
16. Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor.
Meng YG; Singh N; Wong WL
Mol Immunol; 1996; 33(7-8):635-42. PubMed ID: 8760275
[TBL] [Abstract][Full Text] [Related]
17. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
Front Immunol; 2020; 11():832. PubMed ID: 32457754
[TBL] [Abstract][Full Text] [Related]
18. Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.
Li H; Köck K; Wisler JA; Rees WA; Prince PJ; Reynhardt KO; Hsu H; Yu Z; Borie DC; Salinger DH; Pan WJ
Pharmacol Res Perspect; 2015 Feb; 3(1):e00098. PubMed ID: 25692016
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and toxicokinetics assessment of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
Li X; Pang PS; Zhang S; Ru L; Yuan Z; Liu R; Choo QL; Wang Q; Song J; Xu Q; Zhang K; Yu KM; Xu Z
Life Sci; 2020 Oct; 259():118244. PubMed ID: 32791145
[TBL] [Abstract][Full Text] [Related]
20. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.
Xue L; Hickling T; Song R; Nowak J; Rup B
Clin Exp Immunol; 2016 Jan; 183(1):102-13. PubMed ID: 26400440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
